News from genomic health, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 07, 2019, 13:55 ET Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences

Genomic Health, Inc. (NASDAQ: GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp...

Sep 30, 2019, 09:00 ET New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment

Genomic Health, Inc. (NASDAQ: GHDX) today announced results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment (Rx), or...

Aug 21, 2019, 08:00 ET New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer

Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast...

Jul 29, 2019, 07:01 ET Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance

Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2019. The company's...

Jul 25, 2019, 08:00 ET Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m....

Jun 20, 2019, 13:00 ET German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test

Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement decision for the Oncotype DX Breast...

Jun 03, 2019, 11:45 ET Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

Genomic Health, Inc. (NASDAQ: GHDX) today announced that results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment...

Jun 03, 2019, 08:00 ET Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer

Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score® test and the TAILORx results have been recommended...

May 29, 2019, 08:00 ET Genomic Health to Present at the Jefferies 2019 Healthcare Conference

Genomic Health, Inc. (NASDAQ: GHDX) today announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on...

May 07, 2019, 16:05 ET Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress

Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended March 31, 2019. "In the first...

Apr 30, 2019, 08:00 ET Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern...

Mar 25, 2019, 08:00 ET New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test

Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna...

Feb 20, 2019, 16:05 ET Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance

Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2018. "2018...

Feb 13, 2019, 08:00 ET Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m....

Feb 05, 2019, 08:00 ET Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients

Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a multi-center, prospective validation study of the Oncotype DX®...

Jan 07, 2019, 08:00 ET Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes

Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million...

Dec 19, 2018, 08:00 ET NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has...

Dec 18, 2018, 08:00 ET Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference

Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at...

Dec 03, 2018, 16:51 ET Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test

Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular...

Nov 29, 2018, 08:00 ET New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study

enomic Health, Inc. (NASDAQ: GHDX)  and the NSABP Foundation today announced the publication of positive results from a new analysis of the...

Nov 19, 2018, 08:00 ET Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test

Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score®...

Nov 08, 2018, 08:00 ET Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum in...

Nov 06, 2018, 16:05 ET Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance

Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2018. "We continue to...

Oct 30, 2018, 08:00 ET Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m....

Oct 22, 2018, 08:00 ET Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing...